TRxADE HEALTH Inc. (MEDS): Price and Financial Metrics
GET POWR RATINGS... FREE!
MEDS POWR Grades
- Sentiment is the dimension where MEDS ranks best; there it ranks ahead of 68.43% of US stocks.
- The strongest trend for MEDS is in Momentum, which has been heading down over the past 32 days.
- MEDS's current lowest rank is in the Stability metric (where it is better than 11.75% of US stocks).
MEDS Stock Summary
- MEDS has a higher market value than only 3.57% of US stocks; more precisely, its current market capitalization is $21,434,327.
- TRxADE HEALTH INC's stock had its IPO on February 13, 2020, making it an older stock than merely 5.53% of US equities in our set.
- Revenue growth over the past 12 months for TRxADE HEALTH INC comes in at -42.24%, a number that bests only 3.92% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to TRxADE HEALTH INC are HBCP, ESE, SCSC, IZEA, and BMRC.
- Visit MEDS's SEC page to see the company's official filings. To visit the company's web site, go to www.trxadegroup.com.
MEDS Valuation Summary
- In comparison to the median Consumer Defensive stock, MEDS's price/sales ratio is 18.52% higher, now standing at 3.2.
- MEDS's EV/EBIT ratio has moved down 465.8 over the prior 19 months.
- MEDS's EV/EBIT ratio has moved down 465.8 over the prior 19 months.
Below are key valuation metrics over time for MEDS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MEDS | 2021-09-03 | 3.2 | 7.4 | -7.9 | -7.2 |
| MEDS | 2021-09-02 | 3.2 | 7.4 | -7.9 | -7.2 |
| MEDS | 2021-09-01 | 3.2 | 7.2 | -7.8 | -7.1 |
| MEDS | 2021-08-31 | 3.3 | 7.6 | -8.1 | -7.4 |
| MEDS | 2021-08-30 | 3.1 | 7.1 | -7.6 | -6.9 |
| MEDS | 2021-08-27 | 3.1 | 7.2 | -7.7 | -7.0 |
MEDS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MEDS has a Quality Grade of C, ranking ahead of 31.08% of graded US stocks.
- MEDS's asset turnover comes in at 1.191 -- ranking 70th of 105 Wholesale stocks.
- WSTG, AMRK, and CENT are the stocks whose asset turnover ratios are most correlated with MEDS.
The table below shows MEDS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 1.191 | 0.383 | -2.459 |
| 2021-06-30 | 1.389 | 0.323 | -1.537 |
| 2021-03-31 | 1.669 | 0.303 | -0.703 |
| 2020-12-31 | 1.527 | 0.333 | -0.550 |
| 2020-09-30 | 1.656 | 0.406 | -0.162 |
| 2020-06-30 | 1.479 | 0.485 | -0.215 |
MEDS Price Target
For more insight on analysts targets of MEDS, see our MEDS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
MEDS Stock Price Chart Interactive Chart >
MEDS Price/Volume Stats
| Current price | $1.66 | 52-week high | $8.05 |
| Prev. close | $1.62 | 52-week low | $1.16 |
| Day low | $1.59 | Volume | 9,500 |
| Day high | $1.71 | Avg. volume | 232,145 |
| 50-day MA | $1.56 | Dividend yield | N/A |
| 200-day MA | $2.63 | Market Cap | 13.58M |
TRxADE HEALTH Inc. (MEDS) Company Bio
Trxade Group, Inc. provides an on-line platform for pharmaceutical purchasers. It owns and operates a business-to-business web-based marketplace focuses on the United States pharmaceutical industry. It operates web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services; provides state-licensed pharmacies and buying groups in the United States with pharmaceuticals approved by the United States Food and Drug Administration; and acts as technology consultant provider that supports their programming needs and provides research on pharmaceutical pricing and shortages in acute care and retail settings. The company was founded on July 15, 2005 and is headquartered in Land O' Lakes, FL.
Latest MEDS News From Around the Web
Below are the latest news stories about TRxADE HEALTH INC that investors may wish to consider to help them evaluate MEDS as an investment opportunity.
Coborn’s, Inc. and Bonum Health(TM) (A TRxADE HEALTH Company) Ink Telemedicine Deal To Deploy Deeply Discounted Telemedicine to Uninsured and Under-Insured ConsumersTAMPA, FL / ACCESSWIRE /February 23, 2022/ TRxADE HEALTH, INC. (NASDAQ:MEDS) an integrated drug procurement, delivery, healthcare platform and health service company, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a Telemedicine Service Distribution agreement with Coborn's, Inc. |
TRxADE Health Forms Joint Venture SOSRx.com to Expand Medication Accessibility via Manufacturer PartnershipsTAMPA, FL / ACCESSWIRE / February 15, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U. |
TRxADE HEALTH to Present at Aegis Virtual ConferenceTAMPA, FL / ACCESSWIRE / February 9, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U. |
TRxADE HEALTH, INC. Announces Resumption of Modified Stock Repurchase ProgramTAMPA, FL / ACCESSWIRE / December 13, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U. |
Wall Street Analysts Are Bullish on Top Services PicksThere's a lot to be optimistic about in the Services sector as 1 analysts just weighed in on and Trxade Group (MEDS – Research Report) with bullish sentiments. Trxade Group (MEDS) Trxade Group received a Buy rating and a $4.50 price target from EF Hutton analyst EF Hutton yesterday. The company's shares closed last Thursday at $2.93, close to its 52-week low of $2.61. Currently, the analyst consensus on Trxade Group is a Moderate Buy with an average price target of $7.75. |
MEDS Price Returns
| 1-mo | 3.11% |
| 3-mo | -32.79% |
| 6-mo | -36.88% |
| 1-year | -74.46% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -29.66% |
| 2021 | -55.39% |
| 2020 | -19.85% |
| 2019 | N/A |
| 2018 | 0.00% |
| 2017 | N/A |
Loading social stream, please wait...